ArticleJournal of clinical tuberculosis and other mycobacterial diseases2025
Effectiveness and safety of the BPaL regimen in the Philippines.
Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Treatment outcomes and long-term relapse-free survival after multidrug-resistant tuberculosis treatment in Latvia: a retrospective national cohort study.The Lancet regional health. Europe · 2026Article
- High efficacy of BPaL among patients infected withIJTLD open · 2026Article
- Safety of treatment regimens for drug-resistant TB over a 15-year period: a scoping review.IJTLD open · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Treatment success among multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) patients in the Philippines increased with the introduction of a 9-month all-oral treatment regimen; however, this remained sub-optimal, and patients continued to endure the burdensome and toxic effects of component medicines. In 2022, the World Health Organization recommended a 6-month MDR-TB regimen (bedaquiline, pretomanid, and linezolid or BPaL given for 26 weeks). Method: Operational research was conducted in 12 TB treatment centers in 10 regions in the Philippines using the BPaL regimen. From June 2021 to December 2022, patients with pre-extensively drug-resistant TB or MDR/RR-TB that was treatment intolerant or nonresponsive to a previous MDR-TB regimen were enrolled. Linezolid was started daily at either 1200 mg or 600 mg. Results: A total of 103 patients received the BPaL regimen; 96 patients were included in the cohort analysis. Despite fluoroquinolone resistance in 42 %, cavitary TB 31 %, diabetes mellitus 42 %, and HIV coinfection 8 %, treatment success was 98 %, with 1 (1 %) death and 1 (1 %) patient not evaluated. Sputum culture conversion was 78 % at month 1 of treatment, and 96 % by month 4. Sustained success at 6 and 12 months post-treatment were 92 % and 90 %, respectively, with the remainder attributable to patients not returning for post-treatment follow-up.Adverse events were mostly grade 1-2, which fully resolved in almost all patients. Linezolid dose modifications, and BPaL regimen interruption occurred in 66 % and 18 %, respectively. Conclusion: The BPaL regimen had a remarkably high treatment success, rapid culture conversion, and a manageable safety profile among MDR/RR-TB patients in this study despite fluoroquinolone resistance and comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.